Emergent Biosolutions Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent Biosolutions Inc. on December 4, 2015, covering events occurring on December 2, 2015. The filing addresses the departure of a senior executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed relates to a specific executive compensation obligation.
Material Changes
Barry Labinger, Executive Vice President and President of the biosciences division, notified the company on December 2, 2015, that he is terminating his employment effective January 4, 2016. This follows an Executive Retention and Separation Agreement entered into on November 24, 2015.
Outlook, Risks, and Unusual Items
Subject to compliance with the Separation Agreement, the company will pay Mr. Labinger $628,846 over a period of 11.25 months. He is also entitled to other payments, benefits, and rights as detailed in the agreement. The filing references a prior 8-K filed on December 1, 2015, for a full description of the material terms.
Key Facts for Investor Verification
- Effective date of Barry Labinger's departure: January 4, 2016.
- Total separation payment obligation: $628,846.
- Payment duration: 11.25 months.
- Role of departing executive: Executive Vice President and President of the biosciences division.
- Reference to prior filing: Material terms are detailed in the Form 8-K filed on December 1, 2015.